U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06798298) titled 'A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells' on Jan. 09.
Brief Summary: This is a prospective study for the Long-Term Follow-Up (LTFU) of safety and efficacy of all participants exposed to gene modified (GM) T cell therapy in accordance with Health Authorities' guidance for participants treated with gene therapy products.
Participants who received at least one infusion of gene modified T cells in a 2seventy bio (prior to April 2024) or Regeneron Pharmaceuticals sponsored study will be asked to participate in this LTFU protocol, upon either premature discontinuation from, ...